Management ChangeJun 3, 2026, 04:27 PM
Cadrenal Therapeutics CFO Matthew Szot Departs; Interim CFO Appointed
AI Summary
Cadrenal Therapeutics, Inc. announced that Matthew K. Szot mutually agreed to transition from his role as Chief Financial Officer, effective May 28, 2026. Following his departure, CEO Quang X. Pham was appointed as interim Chief Financial Officer and Principal Accounting Officer while the company conducts a search for a permanent replacement. Mr. Szot will receive a severance payment of $365,806 and a fiscal 2026 target cash bonus of $237,903, along with accelerated vesting of all outstanding stock options.
Key Highlights
- Matthew K. Szot transitioned from Chief Financial Officer role effective May 28, 2026.
- Quang X. Pham, CEO, appointed interim Chief Financial Officer and Principal Accounting Officer.
- Mr. Szot will receive a severance payment of $365,806.
- Mr. Szot will receive a fiscal 2026 target cash bonus of $237,903.
- All outstanding stock options issued to Mr. Szot will vest immediately.
- The company is actively searching for a permanent CFO replacement.
Price Impact
More from CVKD